Valuation: Inhalation Sciences Sweden AB

Market Cap	11.62M 1.21M 1.05M 974K 897K 1.69M 116M 1.73M 4.57M 56.85M 4.53M 4.43M 197M	P/E 2024	-12.8x	P/E 2025	-12.4x
Enterprise Value	8.79M 912K 798K 737K 678K 1.28M 87.77M 1.31M 3.46M 43M 3.42M 3.35M 149M	EV / Sales 2024	5.6x	EV / Sales 2025	55x
Free-Float	94.25%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Inhalation Sciences Sweden AB

Dynamic Chart

Latest news : Inhalation Sciences Sweden AB

Jun. 16	Inhalation Sciences Secures SEK 0.4m Research Grant	FW
May. 29	Inhalation Sciences continues to evaluate sale – issues fresh warning over funding shortfall	FW
May. 27	Inhalation Sciences working to secure additional funding	FW
May. 18	Inhalation Sciences Sweden Wins Inhalation Research Services Order	MT
May. 18	Inhalation Sciences secures order worth approximately SEK 1.3 million	FW
May. 18	Inhalation Sciences Sweden AB Receives IRS Order Worth Approximately EUR 117,000	CI
May. 11	Inhalation Sciences posts revenue and order intake growth in Q1	FW
May. 11	Inhalation Sciences Sweden AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 24	Inhalation Sciences secures order worth SEK 350,000	FW
Mar. 24	Inhalation Sciences Sweden AB Secures Additional PreciseInhale Service Orders Worth SEK 350,000	CI
Mar. 03	Inhalation Sciences Raises SEK 2.88 Million Through Warrant Exercise and Directed Share Issue	FW
Feb. 27	Inhalation Sciences Sees Decline in Revenue and Operating Profit – Starts 2026 with Strong Order Backlog	FW
Feb. 27	Inhalation Sciences Sweden AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

More news

Press Releases: Inhalation Sciences Sweden AB

May. 18	Inhalation Sciences receives IRS order worth approximately EUR 117,000	AQ
Mar. 24	Inhalation Sciences: Inhalation Sciences secures additional PreciseInhale® service orders worth SEK 350,000	PU
Mar. 24	Inhalation Sciences secures additional PreciseInhale® service orders worth SEK 350,000	AQ
Feb. 18	Inhalation Sciences receives new IRS order for DissolvIt® worth approximately EUR 139,000	AQ
Jan. 27	Inhalation Sciences: Inhalation Sciences receives new IRS orders worth EUR 52,000 from global pharmaceutical companies	PU

More press releases

Managers and Directors: Inhalation Sciences Sweden AB

Manager	Title	Age	Since
Manoush Masarrat CEO	Chief Executive Officer	-	2019-09-15
Per Magnus Gerde CTO	Chief Tech/Sci/R&D Officer	-	2004-12-31
Ulf Wedenberg PRN	Corporate Officer/Principal	-	2025-06-01

Director	Title	Age	Since
Per Magnus Gerde BRD	Director/Board Member	-	2004-12-31
Niklas Lindecrantz BRD	Director/Board Member	58	2025-06-23
Ulf Ericsson BRD	Director/Board Member	-	2024-08-31

More insiders

Other Advanced Medical Equipment & Technology

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INHALATION SCIENCES SWEDEN AB	+10.19%	+1.79%	-94.77%	-92.17%	1.21M
THERMO FISHER SCIENTIFIC, INC.	-1.97%	+1.03%	+28.39%	+1.68%	198B
DANAHER CORPORATION	-0.58%	+2.40%	+7.25%	-15.35%	144B
INTUITIVE SURGICAL, INC.	-14.15%	-15.08%	-33.40%	-2.68%	122B
BOSTON SCIENTIFIC CORPORATION	-1.32%	-1.65%	-57.52%	-16.63%	65.44B
EDWARDS LIFESCIENCES CORPORATION	-2.40%	-7.03%	+12.08%	-6.81%	49.36B
SIEMENS HEALTHINEERS AG	-0.11%	+1.53%	-23.83%	-30.51%	44.74B
AGILENT TECHNOLOGIES, INC.	-3.41%	-2.11%	+15.33%	+9.95%	37.13B
WATERS CORPORATION	-2.44%	-1.98%	+28.33%	+35.71%	36.23B
RESMED, INC.	-1.86%	-2.39%	-22.85%	-10.01%	28.7B
Average	-1.80%	-1.72%	-14.10%	-12.68%	72.61B
Weighted average by Cap.	-3.69%	-1.84%	-0.99%	-4.99%

See all sector performances

Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Companyâ€™s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Companyâ€™s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Companyâ€™s main shareholder is Nordnet Pensionsforsakring.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
26-07-17	SEK 0.2270	+10.19%	344,846
26-07-16	SEK 0.2060	-5.94%	2,301
26-07-15	SEK 0.2190	0.00%	50,571
26-07-14	SEK 0.2190	0.00%	4,200
26-07-13	SEK 0.2190	-1.79%	13,149

End-of-day quote SPOTLIGHT STOCK MARKET AB

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

1 day	+10.19%
1 week	+1.79%
Current month	-2.99%
1 month	-2.16%
3 months	-15.61%
6 months	-47.45%
Current year	-94.77%

1 week	0.2	0.24
1 month	0.19	0.25
Current year	0.17	0.58
1 year	0.17	0.58
3 years	0.17	4.99
5 years	0.17	11.3
10 years	0.17	15.48

	2024	2025
Net sales	11.05M 1.15M 1M 926K 852K 1.61M 110M 1.65M 4.34M 54.04M 4.3M 4.21M 188M	3.04M 315K 276K 255K 235K 442K 30.36M 453K 1.2M 14.88M 1.18M 1.16M 51.65M
Net income	-5.15M -534K -467K -431K -397K -748K -51.39M -767K -2.02M -25.18M -2M -1.96M -87.42M	-10.16M -1.05M -922K -851K -784K -1.48M -101M -1.51M -3.99M -49.7M -3.96M -3.87M -173M
Net Debt	-4M -415K -363K -335K -309K -582K -39.97M -596K -1.57M -19.58M -1.56M -1.52M -67.99M	-2.83M -294K -257K -237K -218K -412K -28.27M -422K -1.11M -13.85M -1.1M -1.08M -48.08M

Inhalation Sciences Sweden AB Stock

Stocks

ISAB

SE0009983893